Abstract
<h3>Introduction</h3> Berotralstat, an oral once-daily prophylactic treatment for hereditary angioedema (HAE), has demonstrated sustained reduction in HAE attack rates and improvements in patient-reported quality of life in clinical trials. Here we present the preliminary efficacy data of patients in the United States receiving berotralstat in the real-world clinical setting. <h3>Methods</h3> This analysis is data collected through the sole-source pharmacy and included patients with confirmed HAE Type I/II based on laboratory tests and actively received berotralstat 110 or 150mg from 12/16/2020 to 5/20/22 for >270 days. Baseline attack rates were reported for the 90 days prior to berotralstat initiation. While on therapy, median attacks/month (25<sup>th</sup>,75<sup>th</sup> percentile) were calculated over each 90-day period by averaging each patient's monthly reported attack rate (1 month=∼28 days). Some patients did not report attack rates at each refill. <h3>Results</h3> In the patients who actively received berotralstat for >270 days (n=128) the median baseline attack rate was 1.7 attacks/month. A rapid reduction in median monthly attack rates was observed after starting berotralstat. During the first 90 days on therapy (days 1-90) the median monthly attack rate decreased to 0.3 (0,1.50) attacks/month; 0.5 (0,1.00) attacks/month from days 91-180; 0.3 (0,1.25) attacks/month from days 181-270; and 0.3 (0,1.25) attacks/month from days 271-360. The most common adverse events reported were consistent with clinical trials. <h3>Conclusions</h3> This data shows that berotralstat provided a rapid and sustained reduction in HAE attack rates within the first months of starting therapy making oral berotralstat an effective treatment option for patients with HAE.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have